Posters

Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medication with patients with chronic hepatitis C virus infection

Volume 30 · Issue Supplement 1 Publish Date: July 25, 2019
Full Text PDF
DOI
Antoni Sicras Mainar
Scientific Direction Real Life Data Badalona Barcelona Spain
Sabahattin Kaymakoglu
Department of Gastroenterology Istanbul University Istanbul Medical Faculty Istanbul Turkey
Mainar, A. S., & Kaymakoglu, S. (2019). Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medication with patients with chronic hepatitis C virus infection. Turkish Journal of Gastroenterology, 30(Supplement 1), 43–45. https://doi.org/10.5152/tjg.2019.28
Full Text PDF

Abstract

INTRODUCTION: The development of new pangenotypic direct-acting antivirals (pDAA) against hepatitis C virus (HCV) is revolutionizing the treatment of chronic hepatitis C (CHC). The availability of pDAA provides the opportunity to maximize Sustained Virologic Response and minimize side effects and drug-drug interactions. Given the large number of potential concomitant medications and limited pharmacokinetic data, DDIs have become a challenge in the era of DAA, particularly for patients with multiple comorbidities who use concomitant medications. OBJECTIVE: To determine the comorbidity and potential drug-drug interactions (DDIs) among DAAs associated with HCV patients in the usual clinical practice. METHODS: This is a retrospective observational study, designed from the medical records review (computerized database). The study population was obtained from health records of healthcare provider organizations from various centers in Spain (BIG-PAC dissociated database). Patients were ≥18 years diagnosed with HCV, who required medical attention during 2018. Two groups were differentiated according to age ranges (RESULTS: Summary of results obtained 3,430 patients were recruited, the average age was 56.9 years and 60.3% were males. The distribution by age ranges was: CONCLUSION: The subjects with HCV are associated with a high comorbidity and consumption of concomitant medication, especially in older patients (≥50 yrs), a circumstance that results in greater exposure to potential DDI. The use of SOF and LDV/SOF can produce a lower proportion of contraindications (DDIs).

Most read articles by the same author(s)

1 2 3 4 5 > >> 
Article Info
Published In
Journal Turkish Journal of Gastroenterology
Volume / Issue Volume 30 · Issue Supplement 1
Pages 43-45
History
Published Online July 25, 2019
Copyright
Affiliations
Antoni Sicras Mainar
Scientific Direction Real Life Data Badalona Barcelona Spain
Sabahattin Kaymakoglu
Department of Gastroenterology Istanbul University Istanbul Medical Faculty Istanbul Turkey
Cite this Article
Mainar, A. S., & Kaymakoglu, S. (2019). Prevalence of the potential drug-drug interactions between pangenotypic direct-acting antivirals and the concomitant medication with patients with chronic hepatitis C virus infection. Turkish Journal of Gastroenterology, 30(Supplement 1), 43–45. https://doi.org/10.5152/tjg.2019.28
Outlines